Literature DB >> 8562157

Combined therapy for primary central nervous system lymphoma in immunocompetent patients.

A J Ferreri1, M Reni, A Bolognesi, C Verusio, E Villa.   

Abstract

A retrospective series of 13 immunocompetent patients with histological diagnosis of primary central nervous system lymphoma (PCNSL) is presented. The series was divided into Group A, 6 patients treated with radiotherapy alone, and Group B, 7 patients treated with chemotherapy and radiotherapy. Clinicopathological patterns were similar for the two groups. In Group A, 4 patients achieved complete remission after radiotherapy (45-59.4 Gy) but relapsed within 9 months and died within 21 months of diagnosis. 4 Group B patients received chemotherapy followed by radiotherapy, and three who received a methotrexate-containing regimen are alive and disease-free at 34, 42 and 45 months, while the fourth died after 11 months. The other 3 subjects in this group were treated with radiotherapy followed by chemotherapy, and died within 15 months of diagnosis. Although radiotherapy is the standard treatment, chemotherapy has potentially an important role in the management of PCNSL. The sequence of combined treatment could be crucial to improvement of outcome.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8562157     DOI: 10.1016/0959-8049(95)00346-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  6 in total

1.  Hypophyseal non-Hodgkin's lymphoma presenting with diabetes insipidus: a case report.

Authors:  E M Merlo; A Maiolo; A Brocchieri; A Tua; G Grignani
Journal:  J Neurooncol       Date:  1999-03       Impact factor: 4.130

2.  Systemic chemotherapy with vincristine, cyclophosphamide, doxorubicin and prednisolone following radiotherapy for primary central nervous system lymphoma: a phase II study.

Authors:  Y Shibamoto; K Sasai; N Oya; M Hiraoka
Journal:  J Neurooncol       Date:  1999-04       Impact factor: 4.130

3.  White matter lesions and encephalopathy in patients treated for primary central nervous system lymphoma.

Authors:  M W Wassenberg; J E Bromberg; T D Witkamp; C H Terhaard; M J Taphoorn
Journal:  J Neurooncol       Date:  2001-03       Impact factor: 4.130

Review 4.  Neurologic sequelae of treatment of primary CNS lymphomas.

Authors:  U Schlegel; H Pels; R Oehring; I Blümcke
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

5.  Intracerebral Human Lymphoma - An Experimental Model.

Authors:  János Schnur; Andrea Ladányi; László Kopper
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

Review 6.  Second-line treatment for primary central nervous system lymphoma.

Authors:  M Reni; A J Ferreri; E Villa
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.